HighVista Strategies’s CG Oncology CGON Stock Holding History

HighVista Strategies’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Sell	18,867 -1,047	-5%	-$68.4K	0.31%	96
2026 Q1	$1.35M	Sell	19,914 -9,411	-32%	-$533K	0.37%	87
2025 Q4	$1.22M	Buy	29,325 +3,285	+13%	+$136K	0.31%	87
2025 Q3	$1.05M	Buy	26,040 +15,712	+152%	+$457K	0.26%	118
2025 Q2	$269K	Sell	10,328 -11,977	-54%	-$289K	0.1%	139
2025 Q1	$546K	Hold	22,305	–	–	0.21%	124
2024 Q4	$640K	Buy	22,305 +6,571	+42%	+$225K	0.24%	121
2024 Q3	$594K	Buy	+15,734	New	+$552K	0.2%	113

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighVista Strategies's CGON Position: Q2 2026 in Review

HighVista Strategies reduced its CG Oncology (CGON) stake by 5.3% in Q2 2026, selling an estimated $68.4K and leaving 18,867 shares worth $1.34M. The position accounts for 0.31% of the portfolio, ranked #96.

HighVista Strategies first reported a position in CGON in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.35M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

HighVista Strategies held 18,867 shares of CG Oncology worth $1.34M as of Q2 2026.
HighVista Strategies sold 1,047 CG Oncology shares in Q2 2026, an estimated $68.4K.
CG Oncology made up 0.31% of HighVista Strategies's portfolio in Q2 2026, its #96 holding.
HighVista Strategies first reported a position in CG Oncology in Q3 2024 and has held it in 8 quarters since.
HighVista Strategies's CG Oncology position peaked at $1.35M in Q1 2026.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.